Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitravatinib plus Tislelizumab in Advanced ESCC
NCT05461794Phase 2Terminated
- Sponsor
- BeiGene
- Start
- Oct 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sitravatinib in Esophageal Squamous Cell Carcinoma (ESCC) (3 arms), sponsored by BeiGene. Primary endpoint: Overall Response Rate at 12 months. Started Oct 2022; status: terminated.
02
Drugs
sitravatinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05461794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05461794.